Separate from our Oncology/Immunology R&D and commercial operations, our Other Ventures segment mainly provides Shanghai logistics and distribution services to third-party pharmaceutical companies.
This business is operated through a Good Supply Practice-certified joint venture that is 51% owned by HUTCHMED and 49% owned by Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China.
Our Other Ventures also includes Shanghai Hutchison Pharmaceuticals, a non-consolidated joint venture that manufactures, markets and distributes a range of its own-brand prescription drug products across mainland China. This is a joint venture with Shanghai Pharmaceuticals. On January 1, 2025, HUTCHMED agreed to divest most of its 50% interest in Shanghai Hutchison Pharmaceuticals, retaining a 5% interest.